Improved Meal-related Insulin Processing Contributes to the Enhancement of B-Cell Function by the DPP-4 Inhibitor Vildagliptin in Patients with Type 2 Diabetes

Abstract

The aim of this study was to evaluate the contribution of insulin processing to the improved meal-related B-cell function previously shown with the DPP-4 inhibitor vildagliptin. Fifty-five patients with type 2 diabetes (56.5±1.5 years; BMI=29.6±0.5 kg/m²; FPG=9.9±0.2 mmol/l; HbA1c=7.7±0.1 %) were studied: 29 pateients were treated with vildagliptin and 26 patients with placebo, both added to an ongoing metformin regimen (1.5-3.0 g/day). A standardized breakfast was given at baseline and after 52 weeks of treatment, and proinsulin related to insulin secretion was measured with C-peptide in the fasting and postprandial (over 4 h post-meal) states to evaluate B-cell function. The between-treatment difference (vildagliptin-placebo) in mean change from baseline in fasting proinsulin to C-peptide ratio (fastP/C) was -0.007±0.009 (p=0.052). Following the standard breakfast, 52 weeks of treatment with vildagliptin significantly decreased the dynamic proinsulin to C-peptide ratio (dynP/C) relative to placebo by 0.010±0.008 (p=0.037). Importantly, when the P/C was expressed in relation to the glucose stimulus (i.e., the fasting glucose and glucose AUC_{0-240 min}, respectively), the P/C relative to glucose was significantly reduced with vildagliptin vs. placebo, both in the fasting state (p=0.023) and postprandially (p=0.004). In conclusion, a more efficient B-cell insulin processing provides further evidence that vildagliptin treatment ameliorates abnormal B-cell function in patients with type 2 diabetes.

proinsulin to C-peptide ratio - beta-cell function - DPP-4 inhibitor - incretins - GLP-1 - mathematical modeling

References

• 1 Deacon CF, Ahrén B, Holst JJ. Inhibitors of dipeptidyl peptidase IV: a novel approach to prevention and treatment of type 2 diabetes.  Expert Opin Investig Drugs. 2004;  13 1091-1102
• 2 Ahrén B, Gromada J, Schmitz O. Incretin hormones and insulin secretion (Editorial).  Horm Metab Res. 2004;  36 733-734
• 3 Creutzfeldt W. The entero-insular axis in type 2 diabetes-incretins as therapeutic agents.  Exp Clin Endocrinol Diabetes. 2001;  109 ((Suppl 2)) S288-S303
• 4 Villhauer EB, Brinkman JA, Naderi GB, Burkey BF, Dunning BE, Prasad K, Mangold BL, Russell ME, Hughes TE. 1-[[(3-hydroxy-1-adamantyl) amino] acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties.  J Med Chem. 2003;  46 2774-2789
• 5 Ahrén B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels and reduced glucagon levels in type 2 diabetes.  J Clin Endocrinol Metab. 2004;  89 2078-2084
• 6 Ahrén B, Gomis R, Standl E, Mills D, Schweizer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes.  Diabetes Care. 2004;  27 2874-2880
• 7 Stoffers DA. The development of beta-cell mass: recent progress and potential role of GLP-1.  Horm Metab Res. 2004;  36 811-821
• 8 Ahrén B, Pacini G, Foley JE, Schweizer A. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over one year.  Diabetes Care. 2005;  28 1936-1940
• 9 Mari A, Sallas WM, He YL, Watson C, Ligueros-Saylan M, Dunning BE, Deacon CF, Holst JJ, Foley JE. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes.  J Clin Endocrinol Metab. 2005;  90 4888-4894
• 10 Kahn SE. Clinical review 135: the importance of beta-cell failure in the development and progression of type 2 diabetes.  J Clin Endocrinol Metab. 2001;  86 4047-4058
• 11 Thomaseth K, Kautzky-Willer A, Ludvik B, Prager R, Pacini G. Integrated mathematical model to assess β-cell activity during the oral glucose test.  Am J Physiol. 1996;  270 E522-E531
• 12 Tura A, Ludvik B, Nolan JJ, Pacini G, Thomaseth K. Insulin and C-peptide secretion and kinetics in humans: direct and model-based measurements during OGTT.  Am J Physiol. 2001;  281 E966-E974
• 13 Zilker TR, Gray IP, Hales CN, Wahl K, Ermler R, Lebender A, Heinzel G, Bottermann P. Pharmacokinetics of biosynthetic human proinsulin following intravenous and subcutaneous administration in metabolically healthy volunteers.  Horm Metab Res Suppl. 1988;  18 37-43
• 14 Tura A, Pacini G, Kautzky-Willer A, Ludvik B, Prager R, Thomaseth K. Basal and dynamic proinsulin-insulin relationship to assess beta-cell function during OGTT in metabolic disorders.  Am J Physiol. 2003;  285 E155-E162
• 15 Ward WK, LaCava EC, Paquette TL, Beard JC, Wallum BJ, Porte Jr D. Disproportionate elevation of immunoreactive proinsulin in type 2 (non-insulin-dependent) diabetes mellitus and in experimental insulin resistance.  Diabetologia. 1987;  30 698-702
• 16 Ahrén B, Pacini G. Importance of quantifying insulin secretion in relation to insulin sensitivity to accurately assess B-cell function in clinical studies.  Eur J Endocrinol. 2004;  150 97-104
• 17 Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus.  Diabetologia. 2006;  49 2564-2571
• 18 MacDonald PE, El-Kholy W, Riedel MJ, Salapatek AM, Light PE, Wheeler MB. The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion.  Diabetes. 2002;  51 ((Suppl 3)) S434-S442
• 19 Duttaroy A, Voelker F, Zhang X, Ren X, Merriam K, Qiu L, Knight S, Chen H, Hughes T, Burkey B. The DPP-4 inhibitor vildagliptin increases β-cell mass in rodents.  Diabetologia. 2005;  48 ((Suppl 1)) A178

Correspondence